Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.
Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y, Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group. Iwata H, et al. Among authors: kuroi k. Breast Cancer. 2005;12(2):99-103. doi: 10.2325/jbcs.12.99. Breast Cancer. 2005. PMID: 15858439 Free article. Clinical Trial.
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y; Japan Breast Cancer Research Group (JBCRG). Toi M, et al. Among authors: kuroi k. Breast Cancer Res Treat. 2008 Aug;110(3):531-9. doi: 10.1007/s10549-007-9744-z. Epub 2007 Sep 19. Breast Cancer Res Treat. 2008. PMID: 17879158 Clinical Trial.
A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
Aogi K, Saeki T, Nakamura S, Kashiwaba M, Sato N, Masuda N, Rai Y, Ohno S, Kuroi K, Nishimura R, Miyakoda K, Akiyama F, Kurosumi M, Ikeda T. Aogi K, et al. Among authors: kuroi k. Int J Clin Oncol. 2013 Aug;18(4):598-606. doi: 10.1007/s10147-012-0437-1. Epub 2012 Jul 26. Int J Clin Oncol. 2013. PMID: 22833344 Clinical Trial.
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M. Ueno T, et al. Among authors: kuroi k. Int J Clin Oncol. 2014 Aug;19(4):607-13. doi: 10.1007/s10147-013-0614-x. Epub 2013 Oct 8. Int J Clin Oncol. 2014. PMID: 24101215 Free article. Clinical Trial.
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, Yamamoto N, Inoue K, Ohono S, Kuroi K, Hamano T, Sukigara T, Fujiwara Y. Ando M, et al. Among authors: kuroi k. Breast Cancer Res Treat. 2014 Jun;145(2):401-9. doi: 10.1007/s10549-014-2947-1. Epub 2014 Apr 12. Breast Cancer Res Treat. 2014. PMID: 24728578 Clinical Trial.
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M. Yamshiro H, et al. Among authors: kuroi k. Int J Clin Oncol. 2015 Aug;20(4):709-22. doi: 10.1007/s10147-015-0785-8. Epub 2015 Feb 10. Int J Clin Oncol. 2015. PMID: 25666483
152 results